EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$4.56 +0.00% (+$0.00)
1M -64.96%
Market Cap $384.0M
P/E Ratio -
Div. Yield -
ROE 135.81%
Piotroski F-Score Weak
2/9Valuation
40 /100
Fair P/B 2.31x
P/S 137.68x
P/FFO N/A
Growth
22 /100
Declining Book val. growth 47.00%
Rev. growth 8.83%
FCF growth N/A
Profitability
17 /100
Weak Op. margin 11,365.20%
Gross margin 41.77%
FCF margin 9,726.75%
Quality
0 /100
Poor ROA 134.38%
ROIC 167.81%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 4.50x
Debt/Equity 0.13x
Debt/Assets N/A
Stability
37 /100
Moderate EPS volatility 38.17%
Beta 1.74x
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Nadcházející události
04 LIS
Earnings
Upcoming earnings report